June Emerging Medical Technologies Report

Published January 2013 | 39 Pages | 30 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in June 2013.

All companies include technology, market(s), key executive, and contact information.

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


All-in-one blood glucose system containing: the meter, 25 strips, and a lancing device in an integrated, stylish design and the size of a mobile phone
•A pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFREF)
•A suite of products to meet the range of challenges of ischemic stroke, including: 1-a next-generation device that addresses a major limitation of stent-based clot retrieval and 2-a unique, single-lumen catheter designed to enhance the introduction and removal of interventional devices
•Completely non-invasive technology for the treatment of open-angle glaucoma that includes a 5-minute office procedure which has clinically demonstrated the ability to reduce intraocular pressure (IOP) by 25% or more, without medication
•Devices based on proprietary shape memory polymer (SMP) materials, with an initial application in the cerebral aneurysm market
•Disruptive platform with wide applicability across numerous types of cancers: 1-first-generation system that utilizes electromagnetic irradiation to induce regional hyperthermia and 2-second-generation system that utilizes magnetic nanoparticles in conjunction with the first-generation system to deliver superior treatment
•iRaise Sinus Lift System, a minimally invasive alternative to the sinus lift procedure - the most traumatic and difficult procedure performed in the dental clinic today
•IW001 is targeted to idiopathic pulmonary fibrosis (IPF) patients who have autoimmunity against collagen V (40% of all 200,000 IPF patients). IW001 modulates the anti-collagen V immune response and is Phase 2 ready.
•Laparoscopic abdominal port closure device that will bring significant ease of use and cost benefits to the surgeon and enable the surgeon to impart beneficial clinical outcomes to their patients
•Low-cost in vitro antibiotic sensitivity test for use at the point-of-care and designed to deliver results in less than an hour, allowing the correct antibiotic to be prescribed in one hour versus waiting one to four days for lab culture testing results
•New class of active hemostat to replace thrombin in a range of device formulations for the control of surgical bleeding
•Non-invasive brain stimulation for home use, to enable faster and further stroke recovery
•Non-invasive medical devices to protect Diabetics who are susceptible to "hypoglycemia". FDA approved, the Diabetes Sentry is affordable, greatly improves the lives of patients wearing the device, and significantly reduces healthcare costs.
•Non-invasive treatment to correct presbyopia; patients use personalized contact lenses and eye drops for only five days to be lens free for up to 12 months
•Novel technology platform of anti-bacterial compounds based on a family of antimicrobial peptides that are active against multidrug resistant strains
•Patient handling systems for multi-modality suites including: intra-operative MRI's, hybrid OR's, MR/ANGIO and image-guided radiation therapy suites - to simplify the therapy/imaging transitions, improving ROI from the hospital's most expensive assets
•Pipeline of advanced yet affordable systems for blood diagnostics: 1-a benchtop system for hospitals/clinics to screen blood for various parameters, 2-a handheld system to be used at home for patients who are on blood thinning therapy, and 3-a handheld system for multiplexed clinical diagnostics
•Pipeline of novel, targeted biologics and targeted small molecules for oncology, with initial discoveries based on the modulation of apoptotic pathways
•Pulse Flowmeter - a new patient monitor that provides a more sensitive indicator of blood loss or heart failure than monitoring blood pressure
•Revolutionary technology to assess core brain activity using a non-invasive sensor that detects micro-movements of the human eye
•Sales and service for a wide array of diagnostic cameras designed to match the needs of the eye-care industry, including: fundus imagers, confocal microscopes, microperimeters, ultrasound scanners, and corneal topographers
•Sensor to non-invasively and continuously assess patient metabolic status with the goal of bringing ICU level monitoring capability to patients in the emergency department and outside the hospital
•Superficial radiotherapy (SRT) device that safely and cost-effectively treats non-melanoma skin cancers and keloids in hospitals and private practice settings
•System to reverse coronary atherosclerosis by transforming a patient's own plasma into an atherosclerotic reversal agent
•Table top blood analyzer that will allow hospital blood bank directors to learn the quality of blood in storage, which is currently unknown
•The Duette(TM) Bladder Protection Catheter is designed to reduce the clinically confirmed, common adverse effects of traditional Foley catheters, including the occurrence of catheter-associated urinary tract infections (CAUTI)
•The most effective, non-invasive at-home treatment for stress, urge, and mixed female urinary incontinence (UI)
•The only device-based treatment for various conditions known to contribute to Preterm Rupture of Membranes (PROM) and Preterm Birth (the leading cause of infant death and morbidity within the 1st month of life)
•Unique and proprietary iron cobalt magnetic nanoparticles that have significant advantages over and directly replace magnetic iron oxide NP currently consumed by globally installed and new in vitro diagnostic systems
•Very broad-spectrum extracorporeal device that can remove bacteria, bacterial toxins, parasites, viruses, and pro-inflammatory mediators from a patient's blood directly, quickly, and simultaneously

Accelerate your business

We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.